Article Text

Download PDFPDF
Neurofilament light chain and C reactive protein explored as predictors of survival in amyotrophic lateral sclerosis

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Twitter @KoenP4

  • Contributors Concept and design: MDS, CL, PvD, KP. Drafting of the manuscript and figures: MDS, PvD, KP. Acquisition, analysis or interpretation of data: all authors. Critical revision of the manuscript for important intellectual content: all authors.

  • Funding This work was supported by a TBM grant from the Flemish Fund for Scientific Research (FWO-Vlaanderen, no. T003519N). MDS has a PhD Fellowship of FWO-Vlaanderen (11E6319N) and is supported by the Rotary’s ‘Espoir en Tête—Hoofdzaak er is Hoop’. KP received a start-up grant of the Group of Biomedical Sciences KU Leuven and holds a Clinical Research fund of the University Hospitals Leuven. PvD is a senior clinical investigator of the FWO-Vlaanderen and is supported by the ALS Liga België and the KU Leuven funds ‘een Hart voor ALS’, ‘Laeversfonds voor ALS Onderzoek’ and ‘the Valéry Perrier Race against ALS fund’.

  • Disclaimer No funder or sponsor had any role in the design and conduct of the study; collection, management, analysis and interpretation of the data; preparation, review or approval of the manuscript; and decision to submit the manuscript for publication.

  • Competing interests CL participated in a scientific advisory board for Neuraltus, Cytokinetics, Mitsubishi Tanabe (Europe) and Italfarmaco; received research support from Agenzia Italiana per la Ricerca sulla SLA (ARISLA) and Ministry of Health (CCM2011). AC reported serving on the editorial advisory board of Amyotrophic Lateral Sclerosis; received research support from the Italian Ministry of Health (Ricerca Finalizzata), Regione Piemonte (Ricerca Finalizzata), University of Turin, Fondazione Vialli e Mauro onlus and the European Commission (Health Seventh Framework Programme); participated in scientific advisory boards for Biogen, Cytokinetics, Italfarmaco, Neuraltus and Mitsubishi. PvD participated in advisory board meetings for Genzyme, Pfizer, Biogen, Cytokinetics, Mitsubishi Tanabe (Japan), CSL Behring (USA), Alexion Pharmaceuticals (USA). MDS, KP, CT and LM declare no competing interests.

  • Patient consent for publication Obtained.

  • Ethics approval The study was approved by both ethical committees: S50354 (Leuven) and 74-022019 (Milan).

  • Provenance and peer review Not commissioned; externally peer reviewed.